Bank of New York Mellon’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-800
| Closed | -$2.76K | – | 4123 |
|
|
2024
Q3 | $2.76K | Hold |
800
| – | – | ﹤0.01% | 4091 |
|
|
2024
Q2 | $4.06K | Hold |
800
| – | – | ﹤0.01% | 4115 |
|
|
2024
Q1 | $6.77K | Hold |
800
| – | – | ﹤0.01% | 4132 |
|
|
2023
Q4 | $3.27K | Hold |
800
| – | – | ﹤0.01% | 4296 |
|
|
2023
Q3 | $2.4K | Hold |
800
| – | – | ﹤0.01% | 4336 |
|
|
2023
Q2 | $24.7K | Hold |
800
| – | – | ﹤0.01% | 4268 |
|
|
2023
Q1 | $39.6K | Hold |
800
| – | – | ﹤0.01% | 4232 |
|
|
2022
Q4 | $19.7K | Buy |
800
+31
| +4% | +$1.16K | ﹤0.01% | 4359 |
|
|
2022
Q3 | $51K | Hold |
769
| – | – | ﹤0.01% | 4322 |
|
|
2022
Q2 | $32K | Sell |
769
-48
| -6% | -$2.16K | ﹤0.01% | 4436 |
|
|
2022
Q1 | $41K | Hold |
817
| – | – | ﹤0.01% | 4549 |
|
|
2021
Q4 | $49K | Sell |
817
-243
| -23% | -$12K | ﹤0.01% | 4505 |
|
|
2021
Q3 | $52K | Hold |
1,060
| – | – | ﹤0.01% | 4433 |
|
|
2021
Q2 | $61K | Sell |
1,060
-4,846
| -82% | -$259K | ﹤0.01% | 4298 |
|
|
2021
Q1 | $339K | Sell |
5,906
-51
| -0.9% | -$3.85K | ﹤0.01% | 3858 |
|
|
2020
Q4 | $404K | Sell |
5,957
-54
| -0.9% | -$7.35K | ﹤0.01% | 3717 |
|
|
2020
Q3 | $1.53M | Buy |
6,011
+1,132
| +23% | +$232K | ﹤0.01% | 2843 |
|
|
2020
Q2 | $820K | Buy |
4,879
+3,980
| +443% | +$429K | ﹤0.01% | 3216 |
|
|
2020
Q1 | $63K | Buy |
899
+52
| +6% | +$4.06K | ﹤0.01% | 3936 |
|
|
2019
Q4 | $54K | Sell |
847
-117
| -12% | -$6.79K | ﹤0.01% | 4102 |
|
|
2019
Q3 | $56K | Hold |
964
| – | – | ﹤0.01% | 4104 |
|
|
2019
Q2 | $57K | Hold |
964
| – | – | ﹤0.01% | 4105 |
|
|
2019
Q1 | $63K | Sell |
964
-27
| -3% | -$1.54K | ﹤0.01% | 4070 |
|
|
2018
Q4 | $53K | Hold |
991
| – | – | ﹤0.01% | 4052 |
|
|
2018
Q3 | $57K | Sell |
991
-1
| -0.1% | -$60 | ﹤0.01% | 4103 |
|
|
2018
Q2 | $58K | Sell |
992
-256
| -21% | -$15.1K | ﹤0.01% | 4074 |
|
|
2018
Q1 | $59K | Buy |
1,248
+256
| +26% | +$12.9K | ﹤0.01% | 4146 |
|
|
2017
Q4 | $58K | Hold |
992
| – | – | ﹤0.01% | 4184 |
|
|
2017
Q3 | $61K | Hold |
992
| – | – | ﹤0.01% | 4075 |
|
|
2017
Q2 | $62K | Hold |
992
| – | – | ﹤0.01% | 4104 |
|
|
2017
Q1 | $63K | Sell |
992
-32
| -3% | -$1.67K | ﹤0.01% | 4109 |
|
|
2016
Q4 | $39K | Sell |
1,024
-25
| -2% | -$867 | ﹤0.01% | 4158 |
|
|
2016
Q3 | $38K | Sell |
1,049
-166
| -14% | -$6.21K | ﹤0.01% | 4169 |
|
|
2016
Q2 | $44K | Sell |
1,215
-12
| -1% | -$421 | ﹤0.01% | 4190 |
|
|
2016
Q1 | $49K | Buy |
1,227
+12
| +1% | +$441 | ﹤0.01% | 4086 |
|
|
2015
Q4 | $52K | Hold |
1,215
| – | – | ﹤0.01% | 4181 |
|
|
2015
Q3 | $42K | Hold |
1,215
| – | – | ﹤0.01% | 4264 |
|
|
2015
Q2 | $66K | Buy |
1,215
+48
| +4% | +$2.86K | ﹤0.01% | 4127 |
|
|
2015
Q1 | $78K | Buy |
+1,167
| New | +$73.8K | ﹤0.01% | 4094 |
|
Other funds holding BCLI
LWM
HF
WCG
TSS
IC
Bank of New York Mellon's BCLI Position: Q4 2024 in Review
Bank of New York Mellon sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 800 shares — an estimated $2.76K sold.
Bank of New York Mellon first reported a position in BCLI in Q1 2015 and held it in 39 quarters. The position peaked at $1.53M in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.
- Bank of New York Mellon reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
- Bank of New York Mellon sold 800 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $2.76K.
- Bank of New York Mellon first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 39 quarters.
- Bank of New York Mellon's BRAINSTORM CELL THERAPUTC position peaked at $1.53M in Q3 2020.
- 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.
Based on Bank of New York Mellon's 13F filing for Q4 2024, filed 4 Feb 2025.